newsfilter
← Latest News
Business Wire·

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company